KR910007528A - 벤조디아제핀 및 페닐피릴케톤 유도체의 용도 - Google Patents

벤조디아제핀 및 페닐피릴케톤 유도체의 용도 Download PDF

Info

Publication number
KR910007528A
KR910007528A KR1019900017318A KR900017318A KR910007528A KR 910007528 A KR910007528 A KR 910007528A KR 1019900017318 A KR1019900017318 A KR 1019900017318A KR 900017318 A KR900017318 A KR 900017318A KR 910007528 A KR910007528 A KR 910007528A
Authority
KR
South Korea
Prior art keywords
hiv
diseases caused
compound according
effective amount
compound
Prior art date
Application number
KR1019900017318A
Other languages
English (en)
Inventor
흐수 밍-츄
익-카이 탐 스티브
Original Assignee
쟝-자크 오가이. 롤란트 보러
에프. 호프만-라 로슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/428,559 external-priority patent/US5036101A/en
Priority claimed from US07/428,555 external-priority patent/US5070010A/en
Priority claimed from US07/428,558 external-priority patent/US5041438A/en
Application filed by 쟝-자크 오가이. 롤란트 보러, 에프. 호프만-라 로슈 에이지 filed Critical 쟝-자크 오가이. 롤란트 보러
Publication of KR910007528A publication Critical patent/KR910007528A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

내용 없음

Description

벤조디아제핀 및 페닐피릴케톤 유도체의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 7-클로로-5-(2-피릴)-3H-1,4-벤조디아제핀-2(1H)-온 (화합물 A)의 안티-TAT활성을 나타낸다.

Claims (4)

  1. 레트로바이러스에 의해 야기되는 감염성 질환의 치료 또는 예방용, 특히 레트로바이러스 HIV(특히, HIV1)에 의해 야기되는 레트로바이러스성 질환의 세포변성적파괴 작용의 완화용 약제학적 제제를 제조하기 위한, 7-클로로-5-(2-피릴)-3H-1,4-벤조디아제핀-2(1H)-온, 2-글리신아미도-5-클로로페닐(2-피릴)케톤 및 이외 약제학적으로 허용되는 염을 함유하는 그룹의 화합물의 용도.
  2. 제1항에 따른 치료적 유효량의 화합물 및, 임의로 치료적 유효량의 제2의 안티-HIV화합물, 특정하게는 역전사효소 억제제(특히, ddC)를 함유하는, 제1항에 따른 질환의 치료 또는 예방을 위해 경구 또는 비경구투여에 적합한 용량 단위 형태의 항-바이러스 조성물.
  3. 제1항에 따른 용도에 대한 설명서와 함께, 약제학적 활성 성분으로서 제1항에 따른 화합물 및, 임의로 제2항에 따른 제2의 안티-HIV화합물을 함유하는 시판용 패키지.
  4. 주치의에 의해 개별적으로 결정된 일일용량, 특히 일일당 1회 이상 용량의 0.1 내지 10㎎/㎏체중의 항-바이러스 유효량, 바람직하게는 일일당 1회 또는 2회 용량의 1 내지 3㎎/㎏체중의 양(이때 형성된 치료적 형증 수준은 0.05 내지 10. 바람직하게는 0.1 내지 5μM이다)의 제1항에 따른 화합물을 투여하여, 레트로바이러스에 의해 야기되는 감염성 질환의 치료 또는 예방, 특히 레트로바이러스 HIV(특히, HIV 1)에 의해 야기되는 레트로바이러스성 질환의 세포변성적 파괴작용을 완화시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900017318A 1989-10-30 1990-10-29 벤조디아제핀 및 페닐피릴케톤 유도체의 용도 KR910007528A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US07/428,559 US5036101A (en) 1989-10-30 1989-10-30 Method for treating retroviral infections with aryl-(2-pyrryl) ketone compound
US07/428,555 US5070010A (en) 1989-10-30 1989-10-30 Method for determining anti-viral transactivating activity
US428558 1989-10-30
US428559 1989-10-30
US07/428,558 US5041438A (en) 1989-10-30 1989-10-30 Method for treating retroviral infections with benzodiazepine compounds
US428555 1989-10-30

Publications (1)

Publication Number Publication Date
KR910007528A true KR910007528A (ko) 1991-05-30

Family

ID=27411588

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900017318A KR910007528A (ko) 1989-10-30 1990-10-29 벤조디아제핀 및 페닐피릴케톤 유도체의 용도

Country Status (9)

Country Link
EP (1) EP0429868A3 (ko)
JP (1) JPH03151324A (ko)
KR (1) KR910007528A (ko)
AU (1) AU639273B2 (ko)
CA (1) CA2028758A1 (ko)
HU (1) HUT61195A (ko)
IE (1) IE903879A1 (ko)
IL (1) IL96133A0 (ko)
PT (1) PT95733A (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475231A1 (en) * 1990-09-10 1992-03-18 F. Hoffmann-La Roche Ag Benzodiazepines
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
TW221687B (ko) * 1992-01-24 1994-03-11 Hoffmann La Roche
WO1997032587A1 (en) * 1996-03-04 1997-09-12 Dana-Farber Cancer Institute Methods for treating viral infections
TW201111957A (en) * 2009-09-28 2011-04-01 Giga Byte Tech Co Ltd Notebook computer docking station

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122319C (ko) * 1961-06-20

Also Published As

Publication number Publication date
JPH03151324A (ja) 1991-06-27
AU6558990A (en) 1991-05-02
EP0429868A2 (de) 1991-06-05
IL96133A0 (en) 1991-07-18
PT95733A (pt) 1991-09-13
HUT61195A (en) 1992-12-28
EP0429868A3 (en) 1992-04-08
IE903879A1 (en) 1991-05-08
HU906906D0 (en) 1991-05-28
AU639273B2 (en) 1993-07-22
CA2028758A1 (en) 1991-05-01

Similar Documents

Publication Publication Date Title
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
KR930007441A (ko) 의약품
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
RU95121731A (ru) Применение рилузола для лечения нейро-спида и способ получения лекарственного средства
JP2002528502A5 (ko)
KR970061244A (ko) 치매 치료용 약학 조성물
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
KR910007528A (ko) 벤조디아제핀 및 페닐피릴케톤 유도체의 용도
KR890004705A (ko) 항바이러스성 제제
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
BE1002256A3 (fr) Medicaments.
RU93004785A (ru) Твердые капсулы окфосфата цитарабина
WO2000043014A8 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
GB9713549D0 (en) Pharmaceutical combination formulation
Hladovec et al. Oral contraceptives, methionine and endothelial lesion
Chapman et al. Clinical potential of a new HIV protease inhibitor
Batterman et al. ANGINAL SYNDROME—Treatment with a Long-Acting Nitrate (Itramin Tosylate)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid